Why the study?
Degenerative heart valve disease causes significant morbidity, mortality, and healthcare expenditures, prompting an evaluation of evolving indications, evidence, limitations, and future directions for TAVR.
What are the current indications, clinical outcomes, and future directions for transcatheter aortic valve replacement in patients with severe aortic stenosis?
What are the current indications, clinical outcomes, and future directions for transcatheter aortic valve replacement in patients with severe aortic stenosis?
TAVR has expanded from extreme-risk cases to become a standard, frontline therapeutic option for a broad spectrum of patients with severe aortic stenosis.
Reinforces TAVR as standard for severe AS; leaves open refinement of indications and long-term durability.
Degenerative heart valve disease is associated with significant morbidity and mortality and healthcare expenditures. Transcatheter heart valve repair and replacement has introduced a fundamental change in the therapeutic management and transcatheter aortic valve replacement (TAVR) has gained substantial popularity. Favorable results from randomized trials and large real world registries lead to TAVR being considered a standard procedure with high rates of procedural success and low rates of peri-procedural complications. This article aims to review the past evolution, summarize the available evidence, discuss current indications and limitations and venture a glimpse into the future of percutaneous interventions for aortic valve disease.
No takes yet. Share an insight, caveat, or question.
Winkel et al. (2019) conducted a review in Severe aortic stenosis. Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) or medical therapy was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: